Latest news with #AmgenInc
Yahoo
06-07-2025
- Business
- Yahoo
Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab
Amgen Inc. (NASDAQ:AMGN) is one of the . On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers. The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved overall survival in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer with FGFR2b overexpression and who are non-HER2 positive. A pharmacist filling a prescription for a complex drug developed by the company. Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths each year. Bemarituzumab is a first-in-class, Fc-optimized monoclonal antibody that targets FGFR2b, a protein overexpressed in a subset of gastric cancers. Management noted that detailed results will be presented in future meetings, and a separate Phase 3 trial of Bemarituzumab plus chemotherapy and nivolumab is ongoing, with results expected in the second half of 2025. Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that develops innovative medicines for serious diseases with limited treatments. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
04-07-2025
- Business
- Yahoo
Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide exhibited up to ~20% average weight loss in people who are living with obesity without Type 2 diabetes (T2D) as compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people who are living with obesity with T2D in comparison to 1.4% in the placebo arm, per the efficacy estimand. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN) also added that weight loss had not plateaued by 52 weeks, which indicates the potential for further weight reduction. Apart from the meaningful weight loss, MariTide showcased a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% in people who have obesity and T2D. MariTide's monthly or less frequent dosing can improve adherence and long-term weight control. This provides an opportunity to optimize health outcomes for people who have obesity, Type 2 diabetes, and related conditions, highlighted Amgen Inc. (NASDAQ:AMGN). While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below.
Reuters
30-06-2025
- Business
- Reuters
Amgen's gastric cancer drug meets late-stage trial goal
June 30 (Reuters) - Amgen (AMGN.O), opens new tab said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Yahoo
24-06-2025
- Business
- Yahoo
Amgen (AMGN) Falls 5.8% as Novo Nordisk Hammers Its Weight Loss Drug Trial
Amgen Inc. (NASDAQ:AMGN) is one of the . Amgen Inc. extended its losing streak to a fourth straight day on Monday, dropping 5.84 percent to close at $272.44 apiece as investors sold off positions despite positive results from its weight loss drug trial, after Novo Nordisk—maker of the blockbuster Wegovy and Ozempic—progressed in its second obesity drug trial. In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, MariTide, demonstrated up to 20 percent average weight loss in people living with obesity without Type 2 Diabetes (T2D), and up to 17 percent for people living with obesity with T2D. However, investors seemed unimpressed, following Novo Nordisk's announcement over the weekend that its new obesity drug candidate, Amycretin, has progressed to a phase 3 trial after demonstrating 24.3 percent weight loss, higher than Amgen Inc.'s (NASDAQ:AMGN). A pharmacist filling a prescription for a complex drug developed by the company. Additionally, investor sentiment was dampened by an announcement that Amgen Inc.'s (NASDAQ:AMGN) MariTide dosing should be less frequent to improve adherence and long-term weight control. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-06-2025
- Business
- Yahoo
Amgen's Strong Cash Flow Supports Reliable Dividend Payments
Amgen Inc. (NASDAQ:AMGN) is one of the . The company has built a solid track record of dividend growth, supported by consistent cash generation. In the first quarter of 2025, it generated $1.0 billion in free cash flow, up from $0.5 billion in the same period of 2024. The increase was partly due to a one-time $800 million tax payment made in Q1 2024, along with improved business performance, though partially offset by working capital timing and higher capital spending. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN)'s operating cash flow for the quarter rose to $1.4 billion, compared to $0.7 billion a year earlier. During this period, the company returned $1.3 billion to shareholders through dividends, highlighting its ongoing focus on delivering value. As of March 31, 2025, the company held $8.8 billion in cash and cash equivalents, with total debt standing at $57.4 billion. Alongside its consistent dividend growth, Amgen Inc. (NASDAQ:AMGN) stands out as a strong dividend contender due to its modest payout ratio of 44%. This indicates it distributes a sustainable portion of its earnings as dividends while maintaining financial flexibility. Despite significant investments in research and development, the company manages to reward shareholders without straining its balance sheet. Since initiating its dividend in 2011, the company has increased its payout every year. Over the past ten years, the dividend has grown by an impressive 201.3%. It offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.22%, as of June 14. Amgen Inc. (NASDAQ:AMGN) is focused on discovering, developing, producing, and delivering cutting-edge medicines that support millions of patients in battling some of the most challenging diseases worldwide. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
